Eveline Van Keymeulen
Latham & WatkinsThe team at Latham & Watkins, praised for its ‘in-depth’ sector knowledge, particularly in relation to innovative technology in the medtech and biotech sectors. Praised by clients for her ’mastery’ of EU regulation, Eveline Van Keymeulen heads the practice. Having deep knowledge spanning CBD regulatory issues, Van Keymeulen is well-placed to advise clients on cross-border regulatory matters. Jeanne Fabre advises numerous global biotech, medical device, and pharma companies on an array of regulatory issues, including market access, post-market obligations, and clinical trials.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Dynamism, competence and customer focus.’
‘Eveline Van Keymeulen is excellent, both for her precise and relevant analyses of developments in the regulatory environment, and for listening and adapting to client needs.’
‘Highest level team in life sciences. Expert advice, experience and responsiveness.’
‘The team, led by Eveline Van Keymeulen and notably composed of Jeanne Fabre, stands out in particular for its understanding of customer issues, thanks to an analysis and mastery of legal issues without equivalent on the market.’
‘The team stands out for its multidisciplinary expertise covering regulatory matters, clinical trials, marketing and compliance. Their advice is always based on in-depth knowledge of the pharmaceutical, biotechnology and medical device sectors, which allows them to provide comprehensive and practical solutions. I see them as leaders in the field thanks to their ability to navigate complex situations on a European scale.’
‘Eveline Van Keymeulen particularly stands out for her mastery of EU regulatory law. Her ability to solve complex problems in the life sciences is unrivaled. It is also very proactive, allowing companies to anticipate regulatory challenges.’
‘Jeanne Fabre demonstrated excellent business acumen and technical competence. Her knowledge of the dynamics of the healthcare sector, particularly in the regulatory area, makes her a valuable advocate for any company operating in Europe.’
‘These lawyers stand out from their peers with their client-centric approach, in-depth industry knowledge and ability to provide practical, actionable advice.’
Key clients
- Abbott
- AbbVie
- Air Liquide Santé France
- Anne’s Daye (DAYE)
- Argenx
- bioMérieux
- Direct Relief Foundation
- EFPIA (European Federation of Pharmaceutical Industries and Associations)
- Eleusis
- Eli Lilly
- Euronext
- European Sperm Bank
- GlaxoSmithKline
- Inari Medical
- Ipsen
- Ironwood Pharmaceuticals
- Les Laboratoires Servier
- Marinus Pharmaceuticals
- MeiraGTX
- Oncohost
- ProPharma Group
- Resilience Care
- ReCor Medical
- Swedish Orphan Biovitrum AB
- Tempus Labs, Inc.
- Veracyte
- Zoī
Work highlights
- Assisting the European Federation of Pharmaceutical Industries and Associations (EFPIA) in its efforts to collaborate on the revision of the EU pharmaceutical framework, in the context of the European Commission’s Pharmaceutical Strategy for Europe.
- Assisted Marinus Pharmaceuticals Inc. with obtaining a marketing authorization from the European Commission for Ztalmy®, its innovative medicinal product intended as an adjunctive treatment of epileptic seizures in pediatric patients suffering from a rare disease.
- Advising BC Partners, an international investment firm, on the acquisition of a majority stake in Havea, the French leader in natural healthcare serving the European market
Lawyers
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
The lawyer(s) leading their teams.
Eveline Van Keymeulen